← Back to Search

Polyphenol

Oligopin® for Metabolic Syndrome

N/A
Waitlist Available
Led By David Crowley, MD
Research Sponsored by Les Derives Resiniques et Terpeniques
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, day 42 and day 84
Awards & highlights

Summary

The safety and efficacy of Oligopin® will be compared against a placebo to evaluate the effect on metabolic risk factors in subjects with metabolic syndrome. During the 84-day study period it is hypothesized that HDL cholesterol will increase and systolic blood pressure will decrease therefore lowering CVD risk factors after supplementation with Oligopin®. Additionally, it is hypothesized that Oligopin® supplementation will reduce fasting glucose levels.

Eligible Conditions
  • Metabolic Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, day 42 and day 84
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, day 42 and day 84 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Fasting blood sugar level
Secondary study objectives
Alanine aminotransferase (ALT)
Aspartate transaminase (AST)
BMI
+32 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Oligopin®Experimental Treatment1 Intervention
Oligopin® contains French Maritime Pine Bark Extract
Group II: PlaceboPlacebo Group1 Intervention
Placebo is a mixture of different inert compounds
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Oligopin®
2014
N/A
~60

Find a Location

Who is running the clinical trial?

Les Derives Resiniques et TerpeniquesLead Sponsor
KGK Science Inc.Industry Sponsor
78 Previous Clinical Trials
6,120 Total Patients Enrolled
2 Trials studying Metabolic Syndrome
83 Patients Enrolled for Metabolic Syndrome
David Crowley, MDPrincipal InvestigatorKGK Science Inc.
35 Previous Clinical Trials
2,713 Total Patients Enrolled
~8 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top